KRAS and non-small cell lung carcinoma: Overlay visualization maps showed around 2020, researchers focused more on immunotherapy for NSCLC patients with KRAS mutations, and in the past two years, they have focused on targeted drugs such as KRAS-G12C-related targeted therapy research.